This technology uses small molecules to bind HIV Env on infected cells, expose hidden sites, and trigger ADCC, enabling the immune system to kill cells that current therapies cannot reach. By improving antibody recognition and reducing infectious virus production, it provides a complementary approach that directly targets infected cells rather than only preventing new infections.

Published: 12/1/2025